AZ, “We do not consider withdrawing Tagrisso from getting health insurance benefits”
While patient associations are pressing the National Health Insurance Service(NHIS) and AstraZeneca to conclude the drug price negotiation for the company’s non-small cell lung cancer treatment, Tagrisso(generic name: osimertinib), AstraZeneca also said they would do the best for the negotiation ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
